pharma · Advanced Systemic Mastocytosis · Systemic Mastocytosis
Blueprint Medicines
Blueprint Medicines (Netherlands) B.V.
Blueprint Medicines (Netherlands) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Advanced Systemic Mastocytosis, Systemic Mastocytosis, GIST, Indolent Systemic Mastocytosis, Indolen
Cambridge, USA HQ
2011 Founded
741 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2011
- Employees
- 741
- Programs
- 8
- Drugs
- 9
- Patents
- 0
Elenestinib
Phase 3 · small molecule · Indolent Systemic Mastocytosis
Elenestinib for Indolent Systemic Mastocytosis is a Phase 3 program (small_molecule) at Blueprint Medicines (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).
Internal code BLU-263-1201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Blueprint Medicines (Netherlands) B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Indolent Systemic Mastocytosis
- Status
- active
- Trials
- 1